ArticleOpen forum infectious diseases2026
Long-term Rotarix Vaccine Effectiveness in Coastal Kenya, Estimated From Child Hospital Admissions Data From July 2014 to December 2022.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Two doses of Rotarix demonstrated approximately 64% effectiveness against rotavirus hospitalization in Kenyan children 2.5 years postintroduction. We evaluated long-term Rotarix effectiveness and monitored circulating genotypes over its 8.5 years of use in Kenya. Methods: We conducted a test-negative case-control study in coastal Kenya among children admitted to Kilifi County Referral Hospital with diarrhea from July 2014 to December 2022. Eligible children had known Rotarix vaccination status, parent/guardian consent, and rotavirus testing via enzyme-linked immunosorbent assay. Positives were genotyped by sequencing. Rotarix effectiveness was estimated using unconditional logistic regression, adjusting for age, sex, calendar year, seasonality, and nutritional status. Results: Of the 1104 children (median age, 12 months [interquartile range, 8-18 months]) included in the effectiveness analysis, 87% (962/1104) had received 2 doses, 6% (70/1104) 1 dose, and 7% (72/1104) zero doses. Rotavirus was detected in stool specimens of 147 (13%) children. Overall, adjusted 2-dose Rotarix effectiveness was 68% (95% confidence interval [CI], 42%-82%). Effectiveness in children aged <12 months was 83% (95% CI, 62%-93%) compared to 38% (95% CI, -106% to 78%) in children aged ≥12 months. Genotyping of 147 positive samples revealed G3P[8] (66/147 [44.9%]), G1P[8] (32/147 [21.8%]), and G2P[4] (23/147 [15.6%]) to be the most common circulating rotavirus genotypes during the Rotarix vaccination era. Conclusions: Rotarix maintained modest effectiveness in coastal Kenya during its 8.5 years of use. Effectiveness declined in the second year of life onward, probably reflecting a combination of both waning immunity and accumulation of natural immunity among unvaccinated children. Emergence of vaccine heterologous strains emphasizes the need for continued effectiveness surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.